Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2

Advanced Renal Cell Carcinoma Clinical Trial

Official title:

A Two-part, Multiple Dose Clinical Trial Evaluating the Safety and Effectiveness of ABX-EGF in Patients With Renal Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00425035
• Other study ID #: 20020374
• Secondary ID: Abgenix protocol
• Status: Completed
• Phase: Phase 2
• First received: January 18, 2007
• Last updated: May 10, 2013
• Start date: February 2003

Study information

• Verified date: May 2013
• Source: Amgen
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Multicenter, 2-part, multiple-dose study designed to evaluate the safety and effectiveness of weekly administration of panitumumab in subjects with renal carcinoma. Part 1 was initiated in 2001 and will not be presented here. Part 2 was designed to examine a dose of 2.5 mg/kg/wk in 2 cohorts.

Other known NCT identifiers

• NCT00036530

Recruitment information / eligibility

• Status: Completed
• Enrollment: 115
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Able to comprehend and sign an IRB approved Informed Cosent Form

• Male or female 18 years of age or older

• Female patients who are post menopausal (no menstrual period for a minimum of six months), surgically sterilized, or are using an oral or implanted contraceptive, double barrier birth control, or an IUD and have a negative serum pregnancy test upon entry into this study; or male patients willing to use contraception upon enrollment into this study

• Pathologic diagnosis of renal cell carcinoma by fine needle aspirate or tissue biopsy

• Prior nephrectomy

• Prior Therapy:

1. Cohort 1 only: Previously received and failed one prior biotherapy, defined as IL-2 therapy or interferon-alpha (alone or in combination); Karnosky score of > or = 70%

2. Cohort 2 only: No prior therapy except nephrectomy and fall within the Motzer intermediate group with one or two of the risk factors, as defined in teh Study Design section.

• Has bi-dimensionally measurable disease

• Has tumor tissue available for diagnostics (acceptable: biopsy, nephrectomy tissue, fine needle aspirate, or archived tissue that is formalin fixed and paraffin embedded). In cases when a fresh biopsy can be obtained, the biopsy should be divided into two; one half should be formalin fixed, and the other half frozen. Tumor samples must be received at the central laboratory prior to patient regisration.

• Adequate hematologic data, as follows:

1. ANC > 1.5 x 109/L

2. Platelet count > 100x 109/L

• Adequate renal function, as follows:

1. Creatinine < or = 2.2mg/dL

• Adequate hepatic function, as follows:

1. Alkaline phosphatase < or = 3x ULN

2. AST < or = 3x ULN

3. ALT < or = 3x ULN

4. Total bilirubin < or = 1.5x ULN

Exclusion Criteria:

• Brain metastases

• Cohort 1 only: Hypercalcemia (calcium level outside the upper limit of normal; antihypercalcemic treatment is allowed)

• Cancer therapy within 30 days of ABX-EGF infusion (hormone therapy is allowed; steroid therapy is only allowed if it is replacement therapy)

• Use of any investigational drug within 30 days of ABX-EGF infusion

• Prior treatment with any anti-EGFr agents

• Left ventricular ejection fraction < 45%, as measured by MUGA Scan

• Myocardial infarction within one year prior to entering the study

• Has other cancer that has been active and required treatment within the past 5 years (prior renal cell carcinoma, basal cell carcinoma, or cervical carcinoma in situ are allowed)

• Pregnant or breast feeding female; male or female of childbearing potential (defined as: post menarche and is biologically capable of becoming pregnant) unwilling to use birth control (as defined in the inclusion criteria) during and for 1 month following treatment

• Known to be HIV positive

• History of any chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the Investigator may increase the risks associated with study participation or study drug administration or may interfere with the interpretation of study results

• Allergy to the ingredients of the study medication or to Staphylococcus Protein A

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Advanced Renal Cell Carcinoma
• Carcinoma, Renal Cell

Intervention

Drug:
• Panitumumab (ABX-EGF)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Amgen

References & Publications (1)

Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, Arends R, Foon KA, Schwab G, Dutcher J. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 2, Cohort 1: Efficacy: Tumor response rate (CR or PR) measured at 8 weeks
Primary	Part 2, Cohort 1: Safety: Incidence and severity of AEs
Primary	Part 2, Cohort 2: Time to disease progression
Secondary	Part 2, Cohort 1: Time to disease progression
Secondary	Part 2, Cohorts 1 & 2: Survival time
Secondary	Part 2, Cohorts 1 & 2: PFS
Secondary	Part 2, Cohorts 1 & 2: Best overall response rate
Secondary	Part 2, Cohorts 1 & 2: Tumor response rate at Weeks 15, 23, 31, and 39
Secondary	Part 2, Cohorts 1 & 2: Duration of response
Secondary	Part 2, Cohorts 1 & 2: Percent of patients with progressive disease (measured at 8 weeks following initiation of panitumumab treatment)
Secondary	Part 2, Cohorts 1 & 2: Time to CR
Secondary	Part 2, Cohorts 1 & 2: Time to response (PR or CR)

External Links

•   AmgenTrials clinical trials website
•   FDA-approved Drug Labeling